Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 28,193 $ 24,869
Marketable securities 118,130 166,076
Accrued interest receivable 277 687
Prepaid research and development expenses 2,221 9,910
Other prepaid expenses and current assets 2,764 1,381
Total current assets 151,585 202,923
Property and equipment, net 1,761 2,409
Operating lease right-of-use asset 272 235
Other assets 207 160
Total assets 153,825 205,727
Current liabilities:    
Accounts payable 231 2,503
Accrued research and development expenses 4,698 9,218
Accrued restructuring 18 3,193
Other accrued liabilities 4,910 2,722
Total current liabilities 9,857 17,636
Long-term portion of operating lease liability 1,262 1,743
Commitments and contingencies (Note 6)
Total liabilities 11,119 19,379
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 68,946,092 and 68,882,459 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively 7 7
Additional paid-in capital 819,549 812,133
Accumulated other comprehensive income 8 80
Accumulated deficit (676,858) (625,872)
Total stockholders' equity 142,706 186,348
Total liabilities and stockholders' equity $ 153,825 $ 205,727